PADLOCK THERAPEUTICS

Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has completed the previously announced planned acquisition of Padlock Therapeutics, Inc. The transaction includes full rights to Padlock's Protein/Peptidyl Arginine Deiminase inhibitor discovery program focused on the development of potentially transformational treatment approaches for patients with rheumatoid arthritis and other autoimmune diseases. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , and YouTube . Bristol-Myers Squibb Forward-Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of

Also known as: Padlock Therapeutics, Inc.